Quantitative Ocular Surface Changes in Patients Undergoing Immune Checkpoint Inhibitor Therapy

Simple item page
dc.contributor.authorChen, Kevin
dc.contributor.authorBruron, Maria Carolina Ibanez
dc.contributor.authorMondaca, Sebastian
dc.contributor.authorPizarro, Gonzalo
dc.contributor.authorLiberman, Paulina
dc.contributor.authorBerkenstock, Meghan K.
dc.date.accessioned2025-01-20T17:11:46Z
dc.date.available2025-01-20T17:11:46Z
dc.date.issued2024
dc.description.abstractPurposeTo describe the clinical course and evaluate treatment of ocular surface changes in patients receiving immune checkpoint inhibitor (ICI) therapy.MethodsMultiple markers of ocular surface dryness were evaluated in 16 patients on ICI therapy. The Wilcoxon rank-sum test was used to determine the significant change in the initial and final ocular surface indices.ResultsFifty percent of the eyes demonstrated worsening Schirmer I scores; 29% showed an increase in lissamine green staining. During follow-up, 43% of patients experienced a decline in OSDI scores. Treatments included preservative-free artificial tears (88%), cyclosporine (25%), topical corticosteroids (31%), warm compresses (25%); punctal plugs (13%). Median follow-up time was 3.4 months (range:0-79 ); median ICI treatment duration was 7 months (range:1-40). Four patients died during the observation period.ConclusionA significant proportion of patients experience changes in ocular surface markers while treated with ICIs. Medical intervention can lead to stabilization of ocular surface disease.
dc.fuente.origenWOS
dc.identifier.doi10.1080/09273948.2023.2252892
dc.identifier.eissn1744-5078
dc.identifier.issn0927-3948
dc.identifier.urihttps://doi.org/10.1080/09273948.2023.2252892
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/91207
dc.identifier.wosidWOS:001068376900001
dc.issue.numero8
dc.language.isoen
dc.pagina.final1525
dc.pagina.inicio1522
dc.revistaOcular immunology and inflammation
dc.rightsacceso restringido
dc.subjectDry eye disease
dc.subjectimmune checkpoint inhibitor
dc.subjectOSDI
dc.subjectpembrolizumab
dc.subjectSchirmer I
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleQuantitative Ocular Surface Changes in Patients Undergoing Immune Checkpoint Inhibitor Therapy
dc.typeartículo
dc.volumen32
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas